{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:43:11Z","timestamp":1791193391534,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.parkreldis.2014.05.003","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T11:49:43Z","timestamp":1400068183000},"page":"947-956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias"],"prefix":"10.1016","volume":"20","author":[{"given":"Olivier","family":"Rascol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baltazar","family":"Gomez-Mancilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2014.05.003_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mds.870020201","article-title":"Young onset Parkinson's disease","volume":"2","author":"Quinn","year":"1987","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib4","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archneur.62.4.601","article-title":"Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study","volume":"62","author":"Zappia","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson's disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","article-title":"Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease","volume":"64","author":"Nyholm","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.20276","article-title":"Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges","volume":"20","author":"Katzenschlager","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mds.1276","article-title":"Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up","volume":"17","author":"Kanovsky","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garcia Ruiz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","article-title":"Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease","volume":"64","author":"Colzi","year":"1998","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2174\/187152711797247885","article-title":"Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease","volume":"10","author":"Cenci","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.parkreldis.2014.05.003_bib15","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1353-8020(09)70844-2","article-title":"Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease","volume":"15","author":"Antonini","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.parkreldis.2014.05.003_bib16","first-page":"S2","article-title":"The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib18","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study","volume":"23","author":"Snow","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib20","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long-term antidyskinetic efficacy of amantadine in Parkinson's disease","volume":"25","author":"Wolf","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson's disease: the AMANDYSK trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(12)70049-2","article-title":"Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation","volume":"11","author":"Fasano","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib25","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1460-9568.2004.03591.x","article-title":"Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease","volume":"20","author":"Robelet","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuroscience.2009.12.032","article-title":"Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats","volume":"166","author":"Buck","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.nbd.2011.09.015","article-title":"In\u00a0vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels","volume":"45","author":"Mela","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib30","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib31","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.pbb.2011.08.008","article-title":"Overview of glutamatergic neurotransmission in the nervous system","volume":"100","author":"Niciu","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","article-title":"AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys","volume":"54","author":"Konitsiotis","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","article-title":"Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias","volume":"167","author":"Ouattara","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/WNF.0b013e318241520b","article-title":"Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone","volume":"35","author":"Rascol","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib37","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1523\/JNEUROSCI.14-05-03005.1994","article-title":"Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat","volume":"14","author":"Testa","year":"1994","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0891-0618(97)00051-3","article-title":"Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites","volume":"13","author":"Lujan","year":"1997","journal-title":"J\u00a0Chem Neuroanat"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2004.07.005","article-title":"Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia","volume":"17","author":"Konradi","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib40","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib41","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib42","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/13543776.2013.760544","article-title":"mGlu(5) negative allosteric modulators: a patent review (2010-2012)","volume":"23","author":"Emmitte","year":"2013","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib44","unstructured":"PubMed NCBI."},{"key":"10.1016\/j.parkreldis.2014.05.003_bib45","series-title":"Pre-stems: suffixes used in the selection of INN","author":"WHO","year":"2012"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib47","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib49","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-008-0098-4","article-title":"Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats","volume":"115","author":"Gravius","year":"2008","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2012.02.036","article-title":"Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia","volume":"683","author":"Maranis","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.expneurol.2013.09.003","article-title":"Modulating mGluR5 and 5-HT1A\/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action","volume":"250C","author":"Iderberg","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib53","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.neuroscience.2009.07.060","article-title":"Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats","volume":"163","author":"Yamamoto","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib54","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/syn.20941","article-title":"The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-dopa-induced dyskinesias","volume":"65","author":"Marin","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib57","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib58","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib59","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00702-010-0526-0","article-title":"Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L-DOPA-induced dyskinesia","volume":"118","author":"Dekundy","year":"2011","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys","volume":"17","author":"Gregoire","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib61","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib62","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib63","series-title":"ECDEU assessment manual for psychopharmacology","first-page":"534","author":"Guy","year":"1976"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870090103","article-title":"Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology","volume":"9","author":"Marconi","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib65","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/archneur.58.10.1660","article-title":"Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease","volume":"58","author":"Parkinson-Study-Group","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib66","first-page":"153","article-title":"Unified Parkinson's disease rating scale","volume":"vol. 2","author":"Fahn","year":"1987"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib67","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/01.wnl.0000266669.18308.af","article-title":"Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure","volume":"69","author":"Katzenschlager","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib68","article-title":"Merschhemke M, et\u00a0al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients","author":"Kumar","year":"2013","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib69","series-title":"International Congress of Parkinson's Disease and Movement Disorders. Stockholm, Sweden","article-title":"12-week, double-blind, placebo-controlled, fixed-dose study of immediate release AFQ056, an mGluR5 receptor antagonist, in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesias","author":"Stocchi","year":"2014"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib70","series-title":"International Congress of Parkinson's Disease and Movement Disorders. Stockholm, Sweden","article-title":"13-week, double-blind, placebo-controlled, fixed-dose study of modified release AFQ056, an mGluR5 receptor antagonist, in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesias","author":"Trenkwalder","year":"2014"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib71","series-title":"16th International Congress of Parkinson's Disease and Movement Disorders. Dublin, Ireland","article-title":"Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM), in Parkinson's disease patients with levodopa-induced dyskinesia (LID)","author":"Tison","year":"2012"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib72","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A\u00a0five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 study group","volume":"342","author":"Rascol","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/mds.25321","article-title":"Which dyskinesia scale best detects treatment response?","volume":"28","author":"Goetz","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jns.2012.05.029","article-title":"Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia","volume":"319","author":"Suh","year":"2012","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin Pharm"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib76","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","article-title":"Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia","volume":"30","author":"Cenci","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.parkreldis.2014.05.003_bib78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","article-title":"Dopamine-mediated regulation of corticostriatal synaptic plasticity","volume":"30","author":"Calabresi","year":"2007","journal-title":"Trends Neurosci"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:14:09Z","timestamp":1761178449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802014001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1353802014001898"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.05.003","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}